» Articles » PMID: 10595944

Prominent Axonopathy in the Brain and Spinal Cord of Transgenic Mice Overexpressing Four-repeat Human Tau Protein

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1999 Dec 14
PMID 10595944
Citations 137
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the human tau gene cause frontotemporal dementia and parkinsonism linked to chromosome 17. Some mutations, including mutations in intron 10, induce increased levels of the functionally normal four-repeat tau protein isoform, leading to neurodegeneration. We generated transgenic mice that overexpress the four-repeat human tau protein isoform specifically in neurons. The transgenic mice developed axonal degeneration in brain and spinal cord. In the model, axonal dilations with accumulation of neurofilaments, mitochondria, and vesicles were documented. The axonopathy and the accompanying dysfunctional sensorimotor capacities were transgene-dosage related. These findings proved that merely increasing the concentration of the four-repeat tau protein isoform is sufficient to injure neurons in the central nervous system, without formation of intraneuronal neurofibrillary tangles. Evidence for astrogliosis and ubiquitination of accumulated proteins in the dilated part of the axon supported this conclusion. This transgenic model, overexpressing the longest isoform of human tau protein, recapitulates features of known neurodegenerative diseases, including Alzheimer's disease and other tauopathies. The model makes it possible to study the interaction with additional factors, to be incorporated genetically, or with other biological triggers that are implicated in neurodegeneration.

Citing Articles

DLK-MAPK Signaling Coupled with DNA Damage Promotes Intrinsic Neurotoxicity Associated with Non-Mutated Tau.

Li S, Roy E, Wang Y, Watkins T, Cao W Mol Neurobiol. 2023; 61(5):2978-2995.

PMID: 37955806 PMC: 11043018. DOI: 10.1007/s12035-023-03720-1.


Alzheimer's Disease: Significant Benefit from the Yeast-Based Models.

Epremyan K, Mamaev D, Zvyagilskaya R Int J Mol Sci. 2023; 24(12).

PMID: 37372938 PMC: 10298092. DOI: 10.3390/ijms24129791.


Limitations of human tau-expressing mouse models and novel approaches of mouse modeling for tauopathy.

Sahara N, Yanai R Front Neurosci. 2023; 17:1149761.

PMID: 37152607 PMC: 10157230. DOI: 10.3389/fnins.2023.1149761.


Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation?.

Tesco G, Lomoio S Semin Immunol. 2022; 59:101628.

PMID: 35779975 PMC: 9807734. DOI: 10.1016/j.smim.2022.101628.


Structural MRI Reveals Cervical Spinal Cord Atrophy in the P301L Mouse Model of Tauopathy: Gender and Transgene-Dosing Effects.

Sartoretti T, Ganley R, Ni R, Freund P, Zeilhofer H, Klohs J Front Aging Neurosci. 2022; 14:825996.

PMID: 35585865 PMC: 9108240. DOI: 10.3389/fnagi.2022.825996.


References
1.
Harada A, Oguchi K, Okabe S, KUNO J, Terada S, Ohshima T . Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 1994; 369(6480):488-91. DOI: 10.1038/369488a0. View

2.
DSouza I, Poorkaj P, Hong M, Nochlin D, Lee V, Bird T . Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A. 1999; 96(10):5598-603. PMC: 21906. DOI: 10.1073/pnas.96.10.5598. View

3.
Jicha G, Bowser R, Kazam I, Davies P . Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997; 48(2):128-32. DOI: 10.1002/(sici)1097-4547(19970415)48:2<128::aid-jnr5>3.0.co;2-e. View

4.
Behar L, Marx R, Sadot E, Barg J, Ginzburg I . cis-acting signals and trans-acting proteins are involved in tau mRNA targeting into neurites of differentiating neuronal cells. Int J Dev Neurosci. 1995; 13(2):113-27. DOI: 10.1016/0736-5748(95)00001-w. View

5.
Carmel G, Mager E, Binder L, Kuret J . The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem. 1996; 271(51):32789-95. DOI: 10.1074/jbc.271.51.32789. View